Efficacy and safety of oral immunotherapy with short ragweed extract (Q39455312)

12 September 2017

title

Efficacy and safety of oral immunotherapy with short ragweed extract (English)

1 reference

12 September 2017

1 reference

Van Deusen MA

1

1 reference

12 September 2017

Angelini BL

2

1 reference

12 September 2017

Cordoro KM

3

1 reference

12 September 2017

Seiler BA

4

1 reference

12 September 2017

Wood L

5

1 reference

12 September 2017

Skoner DP

6

1 reference

12 September 2017

publication date

1 June 1997

1 reference

Annals of Allergy, Asthma & Immunology

12 September 2017

published in

1 reference

12 September 2017

volume

78

1 reference

12 September 2017

issue

6

1 reference

12 September 2017

page(s)

573-580

1 reference

Systemic reactions from allergen immunotherapy

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

Survey of fatalities from skin testing and immunotherapy 1985-1989.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

Immunologic effects of encapsulated short ragweed extract: a potent new agent for oral immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

Oral immunotherapy in birch pollen hay fever

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

Clinical and immunological effects of oral immunotherapy with a standardized birch pollen extract

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

Safety and efficacy of oral immunotherapy with standardized cat extract

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

Oral administration of grass pollen to hay fever patients. An efficacy study in oral hyposensitization

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

Allergen-specific IgE and IgG antibodies in pollenallergic children given immunotherapy for 2-6 years

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

Immunotherapy with cat- and dog-dander extracts. II. In vivo and in vitro immunologic effects observed in a 1-year double-blind placebo study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

A single year of immunotherapy for ragweed hay fever. Immunologic and clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

High dose grass pollen tablets used for hyposensitization in hay fever patients. A one-year double blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

An assessment of the role of intradermal skin testing in the diagnosis of clinically relevant allergy to timothy grass

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

A multi-institutional trial of polymerized whole ragweed for immunotherapy of ragweed allergy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

A double-blind, placebo-controlled trial of polymerized whole ragweed for immunotherapy of ragweed allergy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

The safety and activity of polymerized ragweed: a double-blind, placebo-controlled trial in 81 patients with ragweed rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963218-8

7 January 2021

10.1016/S1081-1206(10)63218-8

Identifiers

DOI

1 reference

release_c6rz2ndme5bkpfmryqmckf45de

12 September 2017

Fatcat ID

0 references

1 reference